|
Post by agedhippie on Jun 11, 2016 10:44:14 GMT -5
Honestly, I am surprised it didn't move up at the very least by a dollar. The big picture to me is all the doors that JDRF can open. That's because it's no big deal. The JDRF will partner with anyone in the diabetes field.
|
|
|
Post by ilovekauai on Jun 11, 2016 12:46:59 GMT -5
Mango: It will. Just give this a little time to sink in. It's indeed very good news. MNKD is slowly getting its act together after the January shocker & Al Mann's passing. (my hero!). And, I've been putting my money where my mouth is by adding all year long. Afrezza is going to change the way diabetics worldwide relate to their disease. It's going to help millions. Aloha.
|
|
|
PPS
Jun 11, 2016 13:12:02 GMT -5
via mobile
nylefty likes this
Post by sportsrancho on Jun 11, 2016 13:12:02 GMT -5
Mango: It will. Just give this a little time to sink in. It's indeed very good news. MNKD is slowly getting its act together after the January shocker & Al Mann's passing. (my hero!). And, I've been putting my money where my mouth is by adding all year long. Afrezza is going to change the way diabetics worldwide relate to their disease. It's going to help millions. Aloha. And many thanks to the new MNKD posters who infuse the board with their enthusiasm! Finding the stock between 1 and 3 dollars and seeing a great opportunity! I say, lucky you! ( Getting in at the bottom or so) But I can buy more here also, and that's just what I'm going to do AGAIN next week!
|
|
|
Post by victoria on Jun 11, 2016 13:31:26 GMT -5
Honestly, I am surprised it didn't move up at the very least by a dollar. The big picture to me is all the doors that JDRF can open. That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. I don't know about the JDRF, but it does strike me that Sanofi did not partner with them, yet Mannkind has, within just weeks of getting back control. Thats a good thing in my book.
|
|
|
Post by obamayoumama on Jun 11, 2016 13:35:53 GMT -5
Honestly, I am surprised it didn't move up at the very least by a dollar. The big picture to me is all the doors that JDRF can open. That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. If you you are right that it is so "easy" then explain why SNY didn't with Afrezza while they were in control of Afrezza. Sounds like you proved that SNY never tried!
|
|
|
PPS
Jun 11, 2016 14:03:42 GMT -5
Post by mydogskip on Jun 11, 2016 14:03:42 GMT -5
|
|
|
Post by nylefty on Jun 11, 2016 14:25:20 GMT -5
But that wasn't a "new" partnership. In February, JDRF and Sanofi announced the " expansion of their joint research collaboration," which already existed.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 11, 2016 20:09:52 GMT -5
Honestly, I am surprised it didn't move up at the very least by a dollar. The big picture to me is all the doors that JDRF can open. That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. You're right, it's not a big deal at all. In fact, neither is this: —The JDRF Glucose Control Program supports the development of novel insulin formulations and drugs that can be used in conjunction with insulin therapy to provide better control of blood-sugar levels. In summer 2014, JDRF industry partner MannKind received FDA approval for Afrezza, a rapid-acting inhaled insulin that can be used at the beginning of meals to more tightly control the rise in blood-sugar levels that occur after eating. ■ A JDRF-supported study published in the Journal of Diabetes Science and Technology’s May 2015 issue showed that use of Afrezza as a mealtime bolus in conjunction with an experimental AP system significantly increased the percentage of time that people using the system stayed in ideal blood-glucose range. Source: www.kydiabetes.net/images/files/JDRF%2015%20Top%20Research%20Advances.pdfThis isn't a big deal either: —Prevention in the Hands of Future Generations JDRF is funding the Fr1da project, in which 3-and 4-year-olds in Bavaria, Germany, are screened for early-stage markers of T1D at well-child visits. Those who test positive for the markers can enroll in a study monitoring disease progression or a trial testing whether oral insulin can stop progression of T1D. This trial raises the exciting prospect of stopping T1D in its tracks and changing the future for those at risk of developing T1D. Source: jdrf.org/blog/2016/05/20/jdrf-top-advances/You're right, the fact that MannKind has an inhaled insulin, and is entering into a pediatric study with JDRF is definitely not a big deal.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 11, 2016 20:50:00 GMT -5
Mango: It will. Just give this a little time to sink in. It's indeed very good news. MNKD is slowly getting its act together after the January shocker & Al Mann's passing. (my hero!). And, I've been putting my money where my mouth is by adding all year long. Afrezza is going to change the way diabetics worldwide relate to their disease. It's going to help millions. Aloha. And many thanks to the new MNKD posters who infuse the board with their enthusiasm! Finding the stock between 1 and 3 dollars and seeing a great opportunity! I say, lucky you! ( Getting in at the bottom or so) But I can buy more here also, and that's just what I'm going to do AGAIN next week! I went ahead and bought more Friday
|
|
|
PPS
Jun 12, 2016 9:08:57 GMT -5
Post by agedhippie on Jun 12, 2016 9:08:57 GMT -5
That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. You're right, it's not a big deal at all. In fact, neither is this: —The JDRF Glucose Control Program supports the development of novel insulin formulations and drugs that can be used in conjunction with insulin therapy to provide better control of blood-sugar levels. In summer 2014, JDRF industry partner MannKind received FDA approval for Afrezza, a rapid-acting inhaled insulin that can be used at the beginning of meals to more tightly control the rise in blood-sugar levels that occur after eating. ■ A JDRF-supported study published in the Journal of Diabetes Science and Technology’s May 2015 issue showed that use of Afrezza as a mealtime bolus in conjunction with an experimental AP system significantly increased the percentage of time that people using the system stayed in ideal blood-glucose range. Source: www.kydiabetes.net/images/files/JDRF%2015%20Top%20Research%20Advances.pdfThis isn't a big deal either: —Prevention in the Hands of Future Generations JDRF is funding the Fr1da project, in which 3-and 4-year-olds in Bavaria, Germany, are screened for early-stage markers of T1D at well-child visits. Those who test positive for the markers can enroll in a study monitoring disease progression or a trial testing whether oral insulin can stop progression of T1D. This trial raises the exciting prospect of stopping T1D in its tracks and changing the future for those at risk of developing T1D. Source: jdrf.org/blog/2016/05/20/jdrf-top-advances/You're right, the fact that MannKind has an inhaled insulin, and is entering into a pediatric study with JDRF is definitely not a big deal. And exactly which of those moved the price and by how much? I hate to keep hammering this point but JDRF works with anyone in the diabetes space - there is nothing special about this and the market knows that.
|
|
|
PPS
Jun 12, 2016 10:43:33 GMT -5
Post by mydogskip on Jun 12, 2016 10:43:33 GMT -5
But that wasn't a "new" partnership. In February, JDRF and Sanofi announced the " expansion of their joint research collaboration," which already existed. Thanks for pointing that out which makes my point even more valid. Sanofi had no problem extending an existing relationship with JDRF while dropping Afrezza/Mannkind like a hot potato.
|
|
|
Post by victoria on Jun 13, 2016 5:58:47 GMT -5
TASE Price up 4.58% as of 12pm BST As of 12 noon BST, TASE is showing MNKD at 413.20 NIS which is $1.0676 USD, up 4.58% on TASE.
UPDATE: 12.11pm BST now up 5.92% at 418.50 ($1.0810 USD)
|
|
|
Post by hillsave on Jun 13, 2016 8:22:28 GMT -5
Honestly, I am surprised it didn't move up at the very least by a dollar. The big picture to me is all the doors that JDRF can open. That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. You are wrong about JDRF. Their biggest push is the artificial pancreas using Afrezza during mealtime. The director of JDRF IS T1 and he uses Afrezza.
|
|
|
PPS
Jun 13, 2016 9:24:14 GMT -5
Post by mnkdfann on Jun 13, 2016 9:24:14 GMT -5
Honestly, I am surprised it didn't move up at the very least by a dollar. The big picture to me is all the doors that JDRF can open. That's because it's no big deal. The JDRF will partner with anyone in the diabetes field. Yes, I had noticed that the news release came from Mannkind (not JDRF) and there was no like announcement from JDRF, or on JDRF's site. In fact, no mention of Mannkind on the JDRF site jdrf.org at all except a condolence message some months ago concerning Al's passing. I'm not saying the partnering didn't happen, just that JDRF isn't doing much in the way of advertising it.
|
|
|
Post by hillsave on Jun 13, 2016 11:52:23 GMT -5
But that wasn't a "new" partnership. In February, JDRF and Sanofi announced the " expansion of their joint research collaboration," which already existed. Thanks for pointing that out which makes my point even more valid. Sanofi had no problem extending an existing relationship with JDRF while dropping Afrezza/Mannkind like a hot potato. Mannkind had the relationship with JDRF LONG before they partnered with Sanofi. Their collaboration with Mannkind dates back several years when they started to work on the Articial Pancreas
|
|